Posted: Sun Oct 18, 2009 1:35 pm Post subject: ImmuneRegen: Homspera testing Against H5N1
ImmuneRegen BioSciences announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
ImmuneRegen has initiated a study utilizing the highly pathogenic H5N1-Clade 2 virus (the specific virus subtype that has been found to infect humans) to test the efficacy of Homspera in treating ferrets infected with lethal doses of the virus. This study is a continuation of studies previously sponsored by ImmuneRegen testing the efficacy of Homspera in treating the novel H1N1 ("swine flu") Influenza strain currently considered a pandemic by the World Health Organization.
ImmuneRegen is also further evaluating the previously demonstrated vaccine adjuvant effect of Homspera in combination with a vaccine for H5N1. This study is being sponsored by a strategic partner of ImmuneRegen and is utilizing a novel H5N1 antigen and delivery technology.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum